PDS01ADC
Sponsors
National Cancer Institute (NCI)
Conditions
Adrenal Cortex NeoplasmsAdrenal Cortical CarcinomaAdrenal Gland CancerAdrenal Gland NeoplasmsAdrenocortical Carcinoma (ACC)Anal CancerBile Duct CancerBile Duct Neoplasms
Phase 1
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Active, not recruitingNCT04235777
Start: 2020-07-13End: 2028-12-01Updated: 2026-09-08
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
RecruitingNCT04303117
Start: 2020-07-13End: 2028-12-01Target: 80Updated: 2026-08-24
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
RecruitingNCT04633252
Start: 2021-02-23End: 2026-12-31Target: 86Updated: 2026-09-03
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Active, not recruitingNCT04708470
Start: 2021-10-05End: 2026-11-30Updated: 2026-08-31
Phase 2
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RecruitingNCT05286814
Start: 2022-10-24End: 2028-12-31Target: 70Updated: 2026-09-02
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
RecruitingNCT05361798
Start: 2023-06-12End: 2027-12-01Target: 65Updated: 2026-09-18
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
RecruitingNCT06096870
Start: 2024-04-22End: 2029-12-31Target: 65Updated: 2026-09-03